Bausch Health reports $350M third-quarter loss, revenue edges lower

LAVAL, Que. – Bausch Health Companies Inc. reported a loss of $350 million in its latest quarter as its revenue moved lower.

The company formerly known as Valeant Pharmaceuticals says the loss for the quarter ended Sept. 30 amounted to $1.00 per diluted share.

The result compared with a profit of $1.30 billion or $3.69 per share in the same period a year earlier when it benefited from internal tax reorganization.

Revenue totalled nearly $2.14 billion for the quarter, down from nearly $2.22 billion a year ago.

On an adjusted basis, Bausch Health says it earned $403 million in its most recent quarter, up from $367 million in the third quarter of 2017.

The company says the increase was primarily due to lower interest costs and a lower tax rate.

Companies in this story: (TSX:BHC)